Clinical Trials Logo

Ovarian Epithelial Cancer clinical trials

View clinical trials related to Ovarian Epithelial Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03078400 Active, not recruiting - Clinical trials for Ovarian Epithelial Cancer

Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer

Start date: March 10, 2017
Phase: Phase 1
Study type: Interventional

Up to 18 women with ovarian cancer will administer up to two injections of SPL-108 daily in combination with weekly doses of Paclitaxel. They will be monitored for safety and efficacy for up to 6 months, until disease progression or unacceptable toxicity.

NCT ID: NCT02981901 Active, not recruiting - Clinical trials for Ovarian Epithelial Cancer

Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France

Ovaire01
Start date: January 2017
Phase:
Study type: Observational

No structured organization for ovarian first line management emerges in France. Management across France seems to depend on regional contexts. Regions display no specific organization or delineate regional network for the ovarian cancer management or report centralized management revolving around referent centers. These different templates present a major problem in identifying differences, costs and benefit. To deal with this issue the Investigators propose a health economic evaluation based on cost-effectiveness analyses, completed with a budget impact analysis. This study will investigate the cost-effective management of patients with initial ovarian cancer using databases representative of different parts of French territories.

NCT ID: NCT02822157 Active, not recruiting - Clinical trials for Ovarian Epithelial Cancer

Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

CLIO
Start date: August 2016
Phase: Phase 2
Study type: Interventional

This is a randomized, open-label, two-arm study in patients with relapsed epithelial ovarian tumors. Patients will be randomized in a 1:1 ratio to receive olaparib or standard chemotherapy with the possibility of crossover at the time of progression.

NCT ID: NCT01456065 Active, not recruiting - Clinical trials for Ovarian Epithelial Cancer

Safety of Active Immunotherapy in Subjects With Ovarian Cancer

Start date: September 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety of the active immune therapy based on the reiterated injection of fully mature, TERT (Telomerase Reverse Transcriptase)-mRNA and Survivin-peptide double loaded DCs (Dendritic Cells) [Procure®] in patients with advanced ovarian cancer, enrolled into the study within twelve weeks after completing primary therapy.